Evaluating the Safety, Tolerance, Drug Interactions, and Effective Dosing of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in ART-Naive Children Infected With HIV and TB

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2014 by National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01751568
First received: December 14, 2012
Last updated: July 29, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)